GSK Will Prioritize Vaccines and Specialty Medicines in New Agenda

GlaxoSmithKline (GSK) unveiled plans for what it calls the “New GSK,” including focused investment in the development of vaccines and specialty medicines that it predicts will make up the largest share of the company’s revenue within five years.

The planned spinoff of GSK’s consumer healthcare business over the next two years will provide  the UK-based drugmaker with a cash injection for its drug activities, allowing it to prioritize research and development into vaccines and specialty medicines, which are projected to account for three-quarters of all sales by 2026.

Vaccine revenue is expected to climb by high single-digit percentages over five years, the company said.